Abstract
A new series of non-peptidic, mono-acid protein tyrosine phosphatase 1B (PTP1B) inhibitors has been identified by structure-based design. Compounds with 2-(indol-3-yl)- and 2-phenyl-3,3,3-trifluoro-2-hydroxypropionic acid core units targeted at the enzyme's primary site and a hydrophobic chlorophenylthiazole extension in its 2° site exhibit 3-60 µM IC50s for PTP1B inhibition in an Sf9 cell-based assay. © 2007 Elsevier Ltd. All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | 6579-6583 |
| Number of pages | 5 |
| Journal | Bioorganic and Medicinal Chemistry Letters |
| Volume | 17 |
| Issue number | 23 |
| DOIs | |
| Publication status | Published - 1 Dec 2007 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Diabetes
- Indole
- Inhibitor
- Insulin resistance
- Insulin sensitivity
- Obesity
- Phospho-tyrosine
- Protein tyrosine phosphatase 1B
- PTP1B
- Structure-based design
- Thiazole
Fingerprint
Dive into the research topics of '2-Aryl-3,3,3-trifluoro-2-hydroxypropionic acids: A new class of protein tyrosine phosphatase 1B inhibitors'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver